<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119998</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI325A101</org_study_id>
    <nct_id>NCT05119998</nct_id>
  </id_info>
  <brief_title>A Phase I Study of IBI325 in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase I, Open-label, Multicenter, Dose-escalation Study Evaluating the Safety, Tolerability, and Potential Efficacy of IBI325, an Anti-CD73 Antibody, in Patients With Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this phase I study is to evaluate the safety and potential efficacy&#xD;
      and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced&#xD;
      solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 14, 2022</start_date>
  <completion_date type="Anticipated">October 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with DLT</measure>
    <time_frame>28 days post first dose</time_frame>
    <description>Number of patients who experienced a dose-limiting toxicity within the first 28 days after the first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment related AEs</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>Number of patients who experienced a treatment related AEs from the first dose until 90days after the last dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with response</measure>
    <time_frame>Every 6 weeks until progressive disease or up to 24 months after treatment</time_frame>
    <description>Number of patients with response per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUC)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration (Tmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The half-life (t1/2)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of ADA and Nab</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IBI325 and sintilimab combination does-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI325 monotherapy does-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI325 + sintilima</intervention_name>
    <description>IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation</description>
    <arm_group_label>IBI325 and sintilimab combination does-escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI325</intervention_name>
    <description>IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation</description>
    <arm_group_label>IBI325 monotherapy does-escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed, locally advanced unresectable or metastatic tumors.&#xD;
&#xD;
          2. At least one evaluable or measurable lesion per RECIST 1.1&#xD;
&#xD;
          3. Male or female subject at least 18 years old and no more than 75 years old.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0&#xD;
             or 1.&#xD;
&#xD;
          5. Must have adequate organ function&#xD;
&#xD;
          6. Be able to provide archived or fresh tumor tissues-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to any anti-CD73 monoclonal antibody&#xD;
&#xD;
          2. Subjects participating in another interventional clinical study, except for during the&#xD;
             survival follow-up phase of the studies.&#xD;
&#xD;
          3. Unstable central nervous system netastases&#xD;
&#xD;
          4. Known active autoimmune disease or inflammatory disease&#xD;
&#xD;
          5. Known active infectious disease&#xD;
&#xD;
          6. Other uncontrolled systematic disease that may increase the risk of participating the&#xD;
             study-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu Jinming</last_name>
    <phone>0531-67626073</phone>
    <email>sdyujinming@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Province Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Huijuan</last_name>
      <phone>0531-67626073</phone>
      <email>ywb234@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

